Cardiac structure and function in schizophrenia: cardiac magnetic resonance imaging study

Emanuele F. Osimo, Stefan P. Brugger, Antonio de Marvao, Toby Pillinger, Thomas Whitehurst, Ben Statton, Marina Quinlan, Alaine Berry, Stuart A. Cook, Declan P. O’Regan and Oliver D. Howes

Background
Heart disease is the leading cause of death in schizophrenia. However, there has been little research directly examining cardiac function in schizophrenia.

Aims
To investigate cardiac structure and function in individuals with schizophrenia using cardiac magnetic resonance imaging (CMR) after excluding medical and metabolic comorbidity.

Method
In total, 80 participants underwent CMR to determine biventricular volumes and function and measures of blood pressure, physical activity and glycated haemoglobin levels. Individuals with schizophrenia (‘patients’) and controls were matched for age, gender, ethnicity and body surface area.

Results
Patients had significantly smaller indexed left ventricular (LV) end-diastolic volume (effect size d = −0.82, P < 0.001), LV end-systolic volume (d = −0.58, P = 0.02), LV stroke volume (d = −0.85, P = 0.001), right ventricular (RV) end-diastolic volume (d = −0.79, P = 0.002), RV end-systolic volume (d = −0.58, P = 0.02), and RV stroke volume (d = −0.87, P = 0.001) but unaltered ejection fractions relative to controls. LV concentricity (d = 0.73, P = 0.003) and septal thickness (d = 1.13, P < 0.001) were significantly larger in the patients. Mean concentricity in patients was above the reference range. The findings were largely unchanged after adjusting for smoking and/or exercise levels and were independent of medication dose and duration.

Conclusions
Individuals with schizophrenia show evidence of concentric cardiac remodelling compared with healthy controls of a similar age, gender, ethnicity, body surface area and blood pressure, and independent of smoking and activity levels. This could be contributing to the excess cardiovascular mortality observed in schizophrenia. Future studies should investigate the contribution of antipsychotic medication to these changes.

Declaration of interest
S.A.C. is a cofounder and director of Enleofen Bio, a company that develops anti-interleukin-11 therapeutics. D.P.O’R. has received grant funding from Bayer AG. O.D.H. has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Angelini, AstraZeneca, Heptares, Janssen, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche. None of these organisations had any involvement in this study.

Copyright and usage
© The Author(s) 2020. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Schizophrenia is a major mental illness, affecting approximately 0.4–0.7% of the world population, equivalent to 30–52.5 million people. People with schizophrenia have a two- to threefold greater mortality compared with the general population, and their life expectancy is 10–25 years shorter. In addition to the higher suicide risk, mortality due to natural causes has been estimated to be up to eight times higher than expected. Despite reductions in mortality in the general population over the past 30 years (both all-cause and cardiovascular), the mortality gap between people with schizophrenia and the healthy population is not reducing, and may even be increasing. Cardiovascular disease (CVD) accounts for a large proportion of the loss of life in schizophrenia, accounting for 14.3 life-years lost or 60% of deaths, on average, and its importance as a cause of death has been increasing in both US-based and northern European populations. Moreover, people with schizophrenia are less likely to receive investigation and treatment for cardiometabolic comorbidity than the general population, which may contribute to their excess cardiac mortality.

Despite this wealth of epidemiological evidence that associates schizophrenia with cardiovascular disease and premature death, few studies have directly investigated cardiac function in people with schizophrenia. These have generally shown reductions in left ventricular ejection fraction and increases in left ventricular mass in schizophrenia. However, interpretation of these findings is complicated, as the studies did not consistently control for known determinants of cardiovascular structure and function, including body mass index (BMI), gender and comorbid metabolic conditions, which are factors that could independently account for the changes that were found. Consequently, it remains unknown whether schizophrenia is associated with cardiac structural or functional alterations, or whether potential confounds, such as medical and metabolic comorbidity explain the differences reported. Furthermore, previous studies have used transthoracic echocardiography to assess cardiac function, which provides less accurate and less reproducible volumetric and functional assessment of the heart compared with cardiac magnetic resonance imaging (CMR).

In view of this, we aimed to determine whether cardiac structure and function is altered in people with schizophrenia using CMR, the gold standard in vivo measure of cardiac structural and functional assessment. Using a cohort of people with schizophrenia free from metabolic or medical comorbidities and healthy controls matched for known determinants of cardiovascular structure and function, including age, gender, ethnicity and body surface area (BSA), we tested the hypothesis that people with schizophrenia show heart changes that could account for the increased cardiovascular mortality independent of established cardiovascular risk factors such as medical and metabolic comorbidity.
Method

Participants
A total of 40 people with schizophrenia (‘patients’, mean age 39.8 years, s.d. = 9.6 years) were recruited from South London and the Maudsley NHS Foundation Trust and from Central and North West London NHS Foundation Trust in London, UK. A further 40 matched healthy controls (mean age 38.9 years, s.d. = 9.4 years) were recruited after matching for age (±3 years), ethnicity, gender and body surface area (BSA, ±2; BSA is a parameter similar to body mass index, BMI) through the Hammersmith Hospital Healthy Volunteer Panel in London and from the UK Digital Heart Project at Imperial College London (volunteers recruited via advertisement as previously described15). Recruitment took place between September 2015 and December 2018.

Exclusion criteria for all participants were: age <18 or >65 years; pregnancy or breastfeeding; a history of cardiometabolic disease, including diabetes, hypertension, dyslipidaemia, ischaemic heart disease, any vascular disorder, other history of congenital/structural cardiac disease; and history of significant or continuing substance misuse. The inclusion criterion for patients was an ICD-10 diagnosis of schizophrenia. Exclusion criterion for healthy controls was a personal history or first-degree family history of schizophrenia or other psychotic disorder.

Written informed consent was obtained from all volunteers. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human participants were approved by the London – Camberwell St Giles research ethics committee.

Assessment of participants
Physical assessment, study questionnaires, and CMR were all performed during the same study visit. All patients were assessed at the time of CMR imaging using the Positive and Negative Syndrome Scale (PANSS) for Schizophrenia16 by a study psychiatrist. A blood sample for HbA1c was collected from a subsample of 38 matched participants (19 patients and 19 controls). Participants were seated in a quiet, temperature-controlled waiting-room and given time to relax.

A study doctor then performed a screening interview, clinical examination and supervised the CMR scan. The presence of medical comorbidities was assessed directly by interviewing the participants, including diabetes, hypertension, dyslipidaemia, ischaemic heart disease, any vascular disorder, other history of congenital/structural cardiac disease; and history of significant or continuing substance misuse. The inclusion criterion for patients was an ICD-10 diagnosis of schizophrenia. Exclusion criterion for healthy controls was a personal history or first-degree family history of schizophrenia or other psychotic disorder.

Written informed consent was obtained from all volunteers. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human participants were approved by the London – Camberwell St Giles research ethics committee.

Statistical analysis
Differences among patients and controls were tested using χ²-tests for categorical variables, Wilcoxon rank sum tests for non-normally distributed values and analysis of variance (ANOVA) for normally distributed measures. Effect sizes were calculated using Cohen’s d measure.

As there were significant group differences in smoking and physical activity levels, sensitivity analyses were conducted using generalised linear models with smoking, physical activity levels and scanner (1.5 T or 3 T) as covariates, the cardiac measures as the dependent variables and group as the independent variable.

Magnetic resonance imaging protocol
The CMR was performed at a single site for all 80 participants. Owing to a hardware upgrade the first 21 patients and matched controls were scanned on a 1.5 T Philips Achieva (Best, The Netherlands) using a 32-channel cardiac coil and the remaining 19 patients and matched controls were scanned on a 3 T Siemens Magnetom Prisma (Erlangen, Germany) using a combination of the 18-channel body coil and 12 elements of the 32-channel spine coil. Matched patients and controls were scanned on the same scanner. All images used a vectorcardiographic technique for electrocardiogram (ECG) synchronisation and were acquired during breath-hold at expiration. A standard clinical protocol for assessing biventricular function and volumes was followed according to published international guidelines.19 Participants whose images were degraded by respiration or ECG synchronisation artefacts to such an extent that cardiac contours could not be clearly identified were excluded from the analysis. Images were stored on an open-source database.20 Volumetric analysis of the cine images was performed using CMRtools (Cardiovascular Imaging Solutions, London, UK) for Windows by experienced operators masked to the diagnosis. The epicardial and endocardial borders were manually contoured at end-diastole and end-systole in each of the short-axis slices. Semi-automated, signal intensity-based thresholding was then used to identify the papillary muscles; these were included in the left ventricular mass and excluded from volumetric measurements. To increase the accuracy of the analysis, the valve positions at end-diastole and end-systole were manually identified on the three long-axis images, allowing the valve planes to be tracked through the cardiac cycle (Fig. 1).

Volumes and mass were indexed to body surface area calculated using the Mosteller formula:

\[ \text{BSA} = \sqrt{\text{height} \times \text{weight} / 3600} \]

Indexed volumetric data were left ventricular mass (LVmi), left ventricular and right ventricular end-diastolic volumes (LVEDVi and RVEDVi), left ventricular and right ventricular end-systolic volumes (LVESVi and RVESVi), and left ventricular and right ventricular stroke volumes (LVSVi and RVSVi). The end-diastolic volume (EDV) and end-systolic volume (ESV) were calculated using Simpson’s method.21 Stroke volume (SV) was calculated as EDV – ESV and ejection fraction as SV/EDV × 100. Left ventricular mass was the total epicardial volume minus the total endocardial volume multiplied by the specific density of the myocardium (1.05 g/mL). Maximal end-diastolic wall thickness was measured through the basal anteroseptal wall using a short-axis CMR image (Fig. 1(c)). Left ventricular concentricity was calculated as the ratio LVMI/LVEDV. Pulse-wave velocity was calculated using the method described by Corden et al.22 (Fig. 1(d–f)).
To explore the possibility of a dose–response relationship between medication and cardiac phenotypes, linear regression was used to correlate cardiac measures with the natural logarithm of total chlorpromazine equivalents (to normalise the data distribution). The overall proportion of variance explained by linear models was calculated using $R^2$ measures.

$P$-values were adjusted using the Benjamini–Hochberg method, and results were considered significant when the false-discovery rate ($q$) was $<0.05$. Statistical analyses and graph plotting were performed in R (R Foundation for Statistical Computing, 2019, Vienna, Austria) for Mac Os 10.13.

**Results**

A total of 80 participants were recruited for this study. One healthy control had to be excluded because of poor image quality on CMR. Participants’ characteristics are described in Table 1. At the time of assessment, all patients were being treated with antipsychotics (clozapine, $n = 28$; olanzapine, $n = 10$; and risperidone, $n = 2$). There were no significant group differences for age, gender, ethnicity, BSA, HbA1c, systolic and diastolic blood pressure. However, smoking levels and weekly physical activity levels were significantly different between groups.

Cardiac measurements of ventricular structure and function in patients and matched healthy controls

Supplementary Table 1 (available at https://doi.org/10.1192/bjp.2019.268) and Figs 2 and 3 describe CMR-derived measures of cardiac volume and function according to diagnostic status. After adjusting results for multiple testing, patients had significantly smaller LVEDVi ($d = −0.82, F = −11.90, P = 0.001$), LVESVi ($d = −0.58, F = −4.65, P = 0.02$), left ventricular stroke volume ($d = −0.85, F = −7.25, P = 0.001$) (Fig. 2), RVEDVi ($d = −0.79, F = −15.32, P = 0.002$), RVESVi ($d = −0.58, F = −7.36, P = 0.02$) and right ventricular stroke volume ($d = −0.87, F = −8.09, P = 0.001$), with large effect sizes (Fig. 3). Left ventricular concentricity ($d = 0.73, F = 0.13, P = 0.003$) and septal thickness ($d = 1.13, F = 1.71, P < 0.001$) were significantly larger in the patients than in the matched healthy controls, with large to very large effect sizes (Fig. 2). Mean concentricity in patients was above reference ranges for male adult populations, with 77.5% of patients and 41% of controls above the threshold ($\chi^2 = 9.4, \text{d.f.} = 1, P = 0.002$).

The means of all other parameters were within reference ranges in both patients and controls (supplementary Table 1). There were no significant differences between groups in left ventricular mass, biventricular ejection fractions or pulse-wave velocity (supplementary Table 1 and Fig. 1).

Sensitivity analyses

In sensitivity analyses, we explored whether significant differences between patients and controls in terms of cigarettes smoked per day and number of hours of weekly exercise contributed to the differences in cardiac measurements we observed. Supplementary Table 1 shows that, after adjusting the model for the number of cigarettes smoked per day, patients still exhibited significantly smaller LVEDVi ($P = 0.004$), LVESVi ($P = 0.04$), LSVi ($P = 0.003$), RVEDVi ($P = 0.006$), RVESVi ($P = 0.04$) and RSVi ($P = 0.003$),
Potential causes of cardiac remodelling in schizophrenia

The most common cause of concentric heart remodelling in the general population are hypertensive changes, characterised by arteriolar stiffening causing elevated blood pressure. However, we found that in patients with schizophrenia concentric remodelling was present in the absence of signs of clinical or preclinical vascular disease, as demonstrated by blood pressure and pulse-wave velocity, which were both within normal range in patients, and not significantly different from controls. Our findings therefore suggest that concentric heart remodelling in schizophrenia might be a consequence of a separate pathophysiological process.

Interpretation of our findings

This study we found that people with schizophrenia show clinically significant reductions in indexed end-diastolic, end-systolic and stroke volumes in both ventricles (with large effect sizes), while showing an increase in concentricity and septal thickness (with large to very large effect sizes), compared with healthy controls of a similar age, gender, ethnicity, BSA and blood pressure. Mean concentricity in patients was above the reference range, whereas left ventricular concentricity ($P = 0.02$) and septal thickness ($P < 0.001$) were both significantly larger. Significant results were essentially the same if analyses were adjusted for smoking binarised as smoking/not smoking instead (supplementary Table 3). After covarying for physical activity levels, patients exhibited significantly smaller LVEDVi ($P = 0.04$), LVSVi ($P = 0.04$), RVEDVi ($P = 0.04$) and RVSVi ($P = 0.04$), whereas left ventricular concentricity ($P = 0.04$) and septal thickness ($P < 0.001$) were both significantly larger. As smoking and physical inactivity may co-occur, we repeated the analyses covarying for both smoking and physical activity levels. The results remained essentially the same as the physical activity-adjusted analyses (supplementary Table 1). Adjusting for scanner (1.5 v. 3 T) did not affect the significance of any of the results (supplementary Table 3).

In linear regression analyses, no cardiac measure significantly correlated with total current chlorpromazine dose equivalents (supplementary Table 4) or with total chlorpromazine equivalents/years (supplementary Table 5).

In this study we found that people with schizophrenia show clinically significant reductions in indexed end-diastolic, end-systolic and stroke volumes in both ventricles (with large effect sizes), while showing an increase in concentricity and septal thickness (with large to very large effect sizes), compared with healthy controls of a similar age, gender, ethnicity, BSA and blood pressure. Mean concentricity in patients was above the reference range, whereas other measures were significantly different compared with controls, but mean values were within reference ranges. These findings were unchanged in sensitivity analyses adjusting for smoking or exercise levels, other than biventricular end-systolic volumes, which were no longer significantly different. In other words, for the first time to our knowledge, this study shows evidence consistent with concentric remodelling of the heart in schizophrenia. Cardiac remodelling is caused by heart myocytes’ response to noxious stimuli, leading to structural changes, a process that can become pathogenic. Specifically, concentric remodelling is defined as that happening when volumes are normal or reduced, but the left ventricular mass-to-volume ratio is increased. Furthermore, the changes found in our sample of individuals with schizophrenia were independent of conventional cardiometabolic risk factors such as differences in age, gender, ethnicity, medical comorbidity, BSA, HbA1c levels or blood pressure – something that previous studies could not consistently exclude and that could therefore account for the difference in results.

**Implications of our findings**

Concentric cardiac remodelling has been shown to be among the best CMR predictors of future myocardial infarction, coronary insufficiency, heart failure and stroke in healthy adults: individuals in the highest tertile of concentricity showed the lowest cardiovascular disease-free survival over time and steepest slope curves among other common CMR measures, with a hazard ratio for CVD of 1.40 per 0.2 g/mL increase in concentricity. In a separate study, Blumke and colleagues found a hazard ratio for coronary heart disease of 2.1 per g/mL and for stroke of 4.2 per g/mL increase in cardiac concentricity. Concentric heart remodelling was also shown to be a predictor of higher mortality (with a relative risk for all-cause mortality in individuals with concentric remodelling of 1.99) even in people with normal ejection fractions, such as our sample. Finally, increased left ventricular septal thickness, which is increased in our sample, also confers higher cardiovascular morbidity and mortality. The cardiac changes we report could therefore account for part of the increased cardiovascular morbidity and mortality seen in schizophrenia, independent of the increased prevalence of conventional cardiovascular risk factors, such as smoking, associated with schizophrenia.
within the myocardium. In humans, it remains to be determined whether antipsychotics directly act on cardiomyocytes. Aside from this, some, but not all, antipsychotics have been associated with metabolic syndrome, which might mediate cardiovascular risk; individuals with schizophrenia have a tendency to lead a more unhealthy lifestyle than the general population (being more sedentary, smoking more, showing a preference for unhealthy foods). Finally, people with schizophrenia take antipsychotic medication, a medication class, especially second-generation antipsychotics, that has been associated with metabolic syndrome and other cardiovascular risk factors.

Antipsychotic medication as a potential source of heart remodelling
With regard to antipsychotic treatment, there is animal evidence that D2 dopamine receptor signalling contributes to regulating cardiac function. There is also evidence that antipsychotics impair cardioprotection by blocking D2 receptors in a rat model of hypoxia-induced cardiomyocyte injury, thus potentially contributing to cardiac fibrosis. In rats, antipsychotics are also associated with the development of inflammatory lesions and lymphocytic infiltrates within the myocardium. In humans, it remains to be determined whether antipsychotics directly act on cardiomyocytes. Aside from this, some, but not all, antipsychotics have been associated with higher rates of metabolic syndrome, which might mediate cardiovascular changes. Therefore, antipsychotic treatment could account for some of the cardiac changes we demonstrate. However, in our sample we did not find a linear relationship between cardiac changes and current or lifetime antipsychotic dose. The absence of a linear relationship reduces the probability that a causal relationship exists, even if it cannot be ruled out. Additionally, a proportion of our study participants were taking clozapine, a medication that in rare, idiosyncratic occurrences can cause clozapine-induced myocarditis (CIM) and cardiomyopathy (CIC); the estimated combined prevalence of CIM and CIC in clozapine-treated patients is 0.93% (World Health Organization data in Bellissima et al). Furthermore, the median time to onset of myocarditis since starting clozapine is 15 days, and we excluded participants with a history of myocarditis, cardiomyopathy or other cardiac disease. However, could participants with subclinical CIM/CIC be driving our findings? This is unlikely to have a major effect, as (a) less than 1% of clozapine-treated patients experience CIM or CIC so, even if the prevalence of subclinical changes is fourfold higher than the prevalence of clinical CIM/CIC, we would expect it to affect at most one patient in our sample; and (b) clozapine-induced myocarditis/cardio myopathy generally shows an acute presentation over a few days, so it is unlikely that we have scanned patients with emergent CIM/CIC. Moreover, the major long-term sequela of CIM is dilated cardiomyopathy with chronic heart failure, and our findings point in the opposite direction: we find no evidence of heart failure (no change in ejection fractions) and evidence of concentric, rather than dilatatory, changes in our study population. Notwithstanding this, future studies will be useful to clarify the role of clozapine and other antipsychotic medication in the cardiac remodelling we find in schizophrenia.

Pathophysiological mechanisms potentially involved in cardiac remodelling in schizophrenia
We previously found evidence suggesting that an early diffuse myocardial fibrosis and/or subclinical myocardial inflammation are present in the hearts of people with schizophrenia. This would...
suggest that concentric heart remodelling and cardiac fibro-inflammatory changes could both be driven by systemic inflammation, leading to pro-fibrotic stimuli and hence cardiac remodelling with deposition of collagen. In support of this theory, there are established cross-sectional associations between schizophrenia and elevations in peripheral pro-inflammatory cytokines, including interleukin-6 (IL-6) and transforming growth factor \( \beta \) (TGF-\( \beta \)). Furthermore, elevated plasma levels of inflammatory cytokines early in life increase the risk of the subsequent development of a psychotic illness, suggesting that inflammation and psychosis might share a common early developmental aetiology. In particular, TGF-\( \beta \) has been consistently found to be elevated in peripheral blood in the early phases of schizophrenia as compared with healthy controls in several meta-analyses. Finally, animal studies support an aetiological role for TGF-\( \beta \) in causing cardiac fibrosis: in mice, TGF-\( \beta_1 \) has been shown to have cardiac pro-fibrotic properties \textit{in vivo}; in a transgenic model, overexpression of TGF-\( \beta_1 \) resulted in a 38% increase in heart weight, with fibroblast proliferation and collagen synthesis in the myocardium. Therefore, inflammation and elevations in specific pro-inflammatory and pro-fibrotic factors might be mediating cardiac remodelling in schizophrenia, but this will need testing specifically in future studies.

**Strengths and limitations**

A strength of this study is the use of CMR, which is the gold standard for left ventricular function and mass quantification. Key advantages of CMR over echocardiography are (a) that ventricles can be imaged in their entirety and no geometrical assumptions need to be made in order to derive global whole-organ data; and (b) that we were able to perform image analysis masked to participant diagnosis.

Another strength of our study is that, for the first time to our knowledge, participants with a pre-existing diagnosis of any medical condition, including ischaemic heart disease, hypertension, diabetes or dyslipidaemia, were excluded, and we matched patients and controls for BSA, age, gender and ethnicity, all potential confounders in analyses of cardiac function and structure. However, although we excluded diagnosed cardiometabolic disorders, we cannot exclude the possibility of subclinical changes, although we found no significant difference between patients and controls in systolic and diastolic blood pressure or in pulse-wave velocity, and no significant difference in HbA1c in a subsample of our cohort, suggesting that subclinical differences are unlikely to be large.

A limitation of this study is that it involved people with chronic schizophrenia (median duration of treatment of 12 years), who were all taking antipsychotic medications. In addition, 70% of the patient group were taking clozapine and are therefore likely to be treatment resistant, which could affect the generalisability of our findings. We were not powered to detect differences in cardiac structure and function between antipsychotic treatments, and it would be useful for a future study to do this. Thus, a future study in antipsychotic-naive patients would be useful to determine whether
the cardiac differences we detect are associated with treatment or chronicity. Another consideration is that participants were scanned on two different scanners. However, findings remained significant when scanner was included in the analysis. Moreover, recent evidence shows that 1.5 T and 3 T scanners yield similar results for measuring cardiac structure and function, suggesting that the change in equipment is unlikely to have had a major effect on our results.

Future directions
We observed biventricular volume reductions and evidence of concentric cardiac remodelling in patients with schizophrenia compared with matched healthy controls in the absence of concurrent established metabolic or medical risk factors. These are prognostically adverse changes and, in the absence of concurrent conventional metabolic or medical risk factors, could explain part of the additional cardiovascular morbidity and mortality seen in schizophrenia. Further work involving untreated participants is required to disentangle the contribution of antipsychotic medication to cardiac changes in schizophrenia.

Acknowledgements
We thank Alan DeCesare and Pawel F. Tokarczuk for their help in analysing pulse-wave velocity data, and Kristan Skinner for fruitful discussions about the interpretation of our findings.

Emanuele F. Osimo, MSc, MRCPsych, Academic Clinical Fellow in Psychiatry, MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, UK; Antonio de Marvao, MD, PhD, Academic Clinical Fellow in Psychiatry, MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, UK; Toby Pillinger, MD, MRCP, Academic Clinical Fellow in Psychiatry, MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, UK; Thomas Whitehurst, MD, Clinical Research Fellow, MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, UK; Marina Quinlan, MSc, MR Radiographer, MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, UK; Stuart A. Cook, PhD, MRCP, Professor of Clinical and Molecular Cardiology, MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, UK; Alaine Berry, MSc, MR Radiographer, MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, UK; Oliver D. Howes, PhD, MRCPsych, Professor of Molecular Psychiatry, MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, and Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK

Correspondence: Professor Oliver Howes. Email: oliver.howes@kcl.mrc.ac.uk

First received 3 Sep 2019, final revision 8 Nov 2019, accepted 22 Nov 2019

Supplementary material
Supplementary material is available online at http://doi.org/10.1192/bjp.2019.268.

Funding
This study was funded by grants from the British Medical Association, the Medical Research Council, UK (MRC-A656-SQ030) and the National Institute for Health Research (NIHR) Biomedical Research Centre South London and Maudsley Foundation NHS Trust to O.D.H.; and British Heart Foundation grants NA17/312/225 and RG19/1/34387 to D.P.O.T. The study was supported by the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. A.D.M. acknowledges additional support from the Academy of Medical Sciences (SG16/1061) and a MRC Clinical Research Training Grant.

Author contributions
E.F.O. and S.P.B. contributed to the design of the study, recruited and scanned participants, performed data analysis, and drafted the manuscript. A.D.M., B.S., M.Q. and A.B. contributed to study design, cardiac image analysis and revised the manuscript. T.W. and I.P. contributed to participant recruitment and scanning and revised the manuscript. S.A.C. revised the manuscript. D.P.O.T. supervised data analyses and revised the manuscript. O.D.H. conceived and designed the study, supervised data analyses and revised the manuscript. All authors have approved the final manuscript.

Data availability
The dataset for this paper is available on Code Ocean, together with the R analysis codes, so that the analyses can be reproduced (https://doi.org/10.24433/CO.9265392.v1).

References
1 Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2(5): e141.
2 Harris C, Barracough B. Excess mortality of mental disorder. Br J Psychiatry 1999; 173: 11–53.
3 Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012; 25: 83–8.
4 Ösby U, Westman J, Häggren J, Gislér M. Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987–2010. Eur J Public Health 2016; 26: 867–71.
5 Olsson M, Gerhard T, Hwang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72: 1172–81.
6 Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastasso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017; 16: 163–80.
7 Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011; 131: 101–4.
8 Parks J, Swendsen D, Singer P, Foti ME, Maurer B. Mortality and Morbidity in People with Serious Mental Illness. National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council, 2006.
9 Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86: 15–22.
10 Kirmazik S, Kirmazik H, Ozer O, Atmaca M. Assessment of left ventricular systolic and diastolic functions in schizophrenia patients. Psychiatry Res 2016; 240: 348–51.
11 Chow V, Yeeh T, Ng AC, Pasqualon T, Scott E, Plater J, et al. Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study. Open Heart 2014; 1(1): e000030.
12 Unsal C, Oran M, Tureli HO, Alpsoy S, Yesilyurt S, Arslan M, et al. Detection of subclinical atherosclerosis and diastolic dysfunction in patients with schizophrenia. Neuropsy Dis Treat 2013; 9: 1531–7.
13 Bellenger NG, Burgess MI, Ray SG, Lahlou A, Coats AJ, Cleland JG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable? Eur Heart J 2000; 21: 1387–96.
14 Hundleby WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, et al. ACCF/ACR/AHA/ASNC/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010; 55: 2614–62.
15 de Marvao A, Dawes TIW, Shi W, Durigel G, Rueckert D, Cook SA, et al. Precursors of hypertensive heart phenotype develop in healthy adults: a high-resolution 3D MRI study. JACC Cardiovasc Imaging 2015; 8: 1240–9.
16 Kay SR, Fiszbein A, Opier LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophren Bull 1987; 13: 261–76.
17 Dawes TJ, Corden B, Cotter S, de Marvao A, Walsh R, Ware JS, et al. Moderate physical activity in healthy adults is associated with cardiac remodeling. Circ Cardiovasc Imaging 2016; 9(8): e004712.
18 Andreassen NC, Plessier M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010; 67: 255–62.
19 Schult-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic
35 McCreadle RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003; 183: 534–9.
36 Pillinger T, McCutcheon R, Bano J, Mizuno Y, Arumugan A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2019; https://doi.org/10.1016/S2215-0364(19)30416-X.
37 U H, Wei C, Gao J, Bai S, L I, Zhou Y, et al. Mediation of dopamine D2 receptors activation in post-conditioning-attenuated cardiomyocyte apoptosis. Exp Cell Research 2014; 323: 118–30.
38 Nikolovic-Kolic A, Tatalovic N, Nestorov J, Mijovic M, Miljuskovic A, Miller M, et al. Clozapine, ziprasidone, and sertraline-induced morphological changes in the rat heart and their relationship to antioxidant enzymes function. J Toxicol Environ Health A 2018; 81: 844–53.
39 Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet 2002; 359: 248–52.
40 Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841–5.
41 Bellissima BL, Tingle MD, Cicovic A, Alawami M, Kenedi C. A systematic review of clozapine-induced myocarditis. Int J Cardiol 2018; 259: 122–9.
42 Cooper Jr. LT Myocarditis. N Engl J Med 2009; 360: 1526–32.
43 Pillinger T, Osimo EF, de Marvao A, Berry MA, Whitehurst T, Statton B, et al. Cardiac structure and function in patients with schizophrenia taking antipsychotic drugs: an MRI study. Transl Psychiatry 2019; 9: 163.
44 Pillinger T, Osimo EF, Brugger S, Mondelli V, McCutcheon RA, Howes OD. A meta-analysis of immune parameters, variability, and assessment of modal distribution in psychosis and test of the immune subgroup hypothesis. Schizophr Bull 2019; 45: 1120–33.
45 Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 2014; 71: 1121–8.
46 Seeland U, Haeuseler C, Hirnisch R, Rosenkranz S, Pfitzer T, Scharfetter-Kochanek K, et al. Myocardial fibrosis in transforming growth factor-β1 (TGF-β1) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest 2002; 32: 295–303.
47 Aiazz B, Ammar KA, Lopez-Jimenez F, Red.field MM, Jacobsen SJ, Rodeheffer RJ. Abnormal cardiac structure and function in the metabolic syndrome: a population-based study. Mayo Clin Proc 2008; 83: 1350–7.
48 Gandy SJ, Lambert M, Belch J, Cavin I, Crowe E, Littleford R, et al. 3T MRI investigation of cardiac left ventricular structure and function in a UK population: the Tayside Screening for the Prevention of Cardiac Events (TASCFORCE) study. J Magn Reson Imaging 2016; 44: 1186–96.